Department of Obstetrics and Gynecology, The Affiliated Changzhou No.2 People's Hospital of Nanjing Medical University, Changzhou, China.
State Key Laboratory of Reproductive Medicine, Nanjing Medical University;Department of Obstetrics and Gynecology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Front Endocrinol (Lausanne). 2022 Jun 9;13:854345. doi: 10.3389/fendo.2022.854345. eCollection 2022.
BACKGROUND: Endometriosis (EMS) is a relapsing and estrogen-dependent disease. For endometriosis such as deep endometriosis and ovarian endometrioid cysts, surgery is the most effective treatment. Long-term follow-up showed that the recurrence rate of endometriosis after surgical treatment was high, so postoperative drugs were needed to reduce recurrence, and Gonadotropin-releasing hormone agonists (GnRH-a) were the most commonly used drug for postoperative management.GnRH-a may reduce the post-treatment endometriosis relapses by lowering the hormone levels in the body. However, the use of GnRH-a can give rise to perimenopausal symptoms, especially osteoporosis, bone loss, and bone pain, for which reason GnRH-a use is often limited. The add-back therapy is often used to alleviate the untoward effects caused by GnRH-a. However, long-term use of hormone drugs may lead to EMS recurrence, thrombosis, and breast cancer. Therefore, a safer and more effective drug is urgently needed to alleviate the untoward effects caused by GnRH-a. In recent years, scholars at home and abroad have found that isopropanolic Cimicifuga racemosa extract (ICR), as a plant extract, can better relieve the symptoms of perimenopausal women. At the same time, some studies have initially confirmed that black cohosh preparations can relieve the perimenopausal symptoms caused by GnRH-a treatment in EMS patients. OBJECTIVE: To investigate the effect of black cohosh preparations on the bone metabolism of rat models with GnRH-a-induced perimenopausal symptoms. METHODS: The rat models of perimenopausal symptoms were established by GnRH-a injection. and normal saline (NS injection) was used as the control. According to the modeling method and drug intervention, the rats were randomly divided into four groups: GnRH-a injection + saline intervention group (GnRH-a + NS), saline injection control + saline intervention group (NS + NS), GnRH-a injection + estradiol intervention group (GnRH-a + E2), and GnRH-a injection + black cohosh preparation intervention group (GnRH-a + ICR). The rat models were identified with the vaginal smear method, and then the corresponding drug intervention was administrated for 28 days. After the intervention, the rats were sacrificed. The rats' bone mineral density (BMD) of the distal femur was detected by a dual-energy X-ray bone density scanner. Rat tibia bone tissues were decalcified and made into slices. The pathological and morphological changes of rat tibial bones in each group were observed through HE staining. Histomorphometry parameters of rat tibial bones in each group, such as trabecular bone volume (TBV), trabecular thickness (TbTh), trabecular number (TbN), and trabecular spacing (TbSp), were detected and analyzed by using an automatic image analysis system. RESULTS: (1) The BMD level of the distal femur in the GnRH-a + NS group was significantly lower than the NS + NS, GnRH-a + E2, and GnRH-a + ICR groups (<0.01), the BMD levels in GnRH-a + E2 and GnRH-a + ICR groups were slightly lower than the NS + NS group, but there was no significant difference among the three groups (>0.05). (2) The pathological changes of the tibia bones under the microscope in different groups were as follows: The tibia bone trabecular structure was normal in the NS + NS group, without trabecular thinning or fracture, and the arch structure was normal. In the GnRH-a + NS group, some trabecular structures tapered, the arch structure disappeared, but no obvious bone fracture was observed in the trabecula. In the GnRH-a + E2 and GnRH-a + ICR groups, the trabecular structures were normal, without trabecular bone thinning or fracture, and the arch structures were normal. (3) The TBV level of the GnRH-a + INS group was significantly lower than that of the NS + NS, GnRH-a + E2 and GnRH-a + ICR groups (<0.01, <0.05, <0.01), while there was no significant difference among NS + NS, GnRH-a + E2 and GnRH-a + ICR groups (>0.05). (4) The TbTh levels in the four groups had no significant difference (>0.05). Compared with the NS + NS group, the TbTh levels in the GnRH-a + NS, GnRH-a + E2, and GnRH-a + ICR groups showed a descending tendency, while the TbTh levels in the GnRH-a + E2 and GnRH-a + ICR groups were slightly higher than that of the GnRH-a + NS group. However, such differences were not significant statistically (P>0.05). (5) Compared with the NS + NS group, the TbN levels in the GnRH-a + NS, GnRH-a + E2, and GnRH-a + ICR groups decreased remarkably (<0.05). Compared with the GnRH-a + NS group, the TbN levels in the GnRH-a + E2 and GnRH-a + ICR groups showed a mild descending tendency, but such differences were not significant statistically (>0.05). (6) The TbSp level of the GnRH-a + NS group was significantly higher than that of the NS + NS, GnRH-a + E2, and GnRH-a + ICR groups (<0.01), while there was no significant difference among NS + NS, GnRH-a + E2 and GnRH-a + ICR groups (>0.05). CONCLUSION: The GnRH-a injection could achieve the desired effect. GnRH-a injection may lead to the loss of bone mass in rats. Black cohosh preparations, like estrogen, may have a protective effect on bone mass loss caused by GnRH-a injection.
背景:子宫内膜异位症(EMS)是一种复发性和雌激素依赖性疾病。对于深部子宫内膜异位症和卵巢子宫内膜样囊肿等疾病,手术是最有效的治疗方法。长期随访显示,手术后子宫内膜异位症的复发率较高,因此需要术后药物治疗以降低复发率,促性腺激素释放激素激动剂(GnRH-a)是最常用的术后管理药物。 GnRH-a 可能通过降低体内激素水平来降低治疗后子宫内膜异位症的复发率。然而, GnRH-a 的使用会引起围绝经期症状,尤其是骨质疏松症、骨丢失和骨痛,因此 GnRH-a 的使用往往受到限制。添加治疗通常用于缓解 GnRH-a 引起的不良反应。然而,长期使用激素药物可能导致 EMS 复发、血栓形成和乳腺癌。因此,迫切需要一种更安全、更有效的药物来缓解 GnRH-a 引起的不良反应。近年来,国内外学者发现,异丙醇 Cimicifuga racemosa 提取物(ICR)作为一种植物提取物,可以更好地缓解围绝经期妇女的症状。同时,一些研究初步证实,黑升麻制剂可以缓解 GnRH-a 治疗 EMS 患者引起的围绝经期症状。
目的:探讨黑升麻制剂对 GnRH-a 诱导围绝经期症状大鼠模型骨代谢的影响。
方法:采用 GnRH-a 注射建立围绝经期症状大鼠模型,并用生理盐水(NS 注射)作为对照。根据建模方法和药物干预,将大鼠随机分为 GnRH-a 注射+生理盐水干预组(GnRH-a+NS)、生理盐水注射对照组+生理盐水干预组(NS+NS)、 GnRH-a 注射+雌二醇干预组(GnRH-a+E2)和 GnRH-a 注射+黑升麻制剂干预组(GnRH-a+ICR)。通过阴道涂片法鉴定大鼠模型,然后给予相应的药物干预 28 天。干预结束后,处死大鼠。使用双能 X 射线骨密度扫描仪检测大鼠远端股骨的骨密度(BMD)。对大鼠胫骨骨组织进行脱钙和切片。通过 HE 染色观察各组大鼠胫骨的病理和形态变化。使用自动图像分析系统检测和分析各组大鼠胫骨的组织形态计量学参数,如骨小梁体积(TBV)、骨小梁厚度(TbTh)、骨小梁数量(TbN)和骨小梁间距(TbSp)。
结果:(1) GnRH-a+NS 组大鼠股骨远端 BMD 水平明显低于 NS+NS、 GnRH-a+E2 和 GnRH-a+ICR 组(<0.01), GnRH-a+E2 和 GnRH-a+ICR 组大鼠股骨远端 BMD 水平略低于 NS+NS 组,但组间差异无统计学意义(>0.05)。(2)不同组大鼠胫骨骨显微镜下的病理变化如下:NS+NS 组胫骨骨小梁结构正常,无骨小梁变薄或骨折,拱形结构正常。在 GnRH-a+NS 组中,一些骨小梁结构变细,拱形结构消失,但在小梁中没有明显的骨折。在 GnRH-a+E2 和 GnRH-a+ICR 组中,骨小梁结构正常,无骨小梁变薄或骨折,拱形结构正常。(3) GnRH-a+INS 组的 TBV 水平明显低于 NS+NS、 GnRH-a+E2 和 GnRH-a+ICR 组(<0.01、<0.05、<0.01),而 NS+NS、 GnRH-a+E2 和 GnRH-a+ICR 组之间无显著差异(>0.05)。(4)四组大鼠的 TbTh 水平无显著差异(>0.05)。与 NS+NS 组相比, GnRH-a+NS、 GnRH-a+E2 和 GnRH-a+ICR 组的 TbTh 水平呈下降趋势,而 GnRH-a+E2 和 GnRH-a+ICR 组的 TbTh 水平略高于 GnRH-a+NS 组。然而,这些差异没有统计学意义(P>0.05)。(5)与 NS+NS 组相比, GnRH-a+NS、 GnRH-a+E2 和 GnRH-a+ICR 组的 TbN 水平明显降低(<0.05)。与 GnRH-a+NS 组相比, GnRH-a+E2 和 GnRH-a+ICR 组的 TbN 水平呈轻微下降趋势,但差异无统计学意义(>0.05)。(6) GnRH-a+NS 组大鼠的 TbSp 水平明显高于 NS+NS、 GnRH-a+E2 和 GnRH-a+ICR 组(<0.01),而 NS+NS、 GnRH-a+E2 和 GnRH-a+ICR 组之间无显著差异(>0.05)。
结论: GnRH-a 注射可达到预期效果。 GnRH-a 注射可能导致大鼠骨量丢失。黑升麻制剂可能像雌激素一样对 GnRH-a 注射引起的骨量丢失具有保护作用。
Front Endocrinol (Lausanne). 2021
J Bone Miner Res. 2005-11
Rejuvenation Res. 2016-6
Zhongguo Zhong Xi Yi Jie He Za Zhi. 2014-11
Int J Womens Health. 2023-5-12
Front Endocrinol (Lausanne). 2021
Rev Endocr Metab Disord. 2022-6
Expert Opin Investig Drugs. 2021-9
Zhejiang Da Xue Xue Bao Yi Xue Ban. 2020-5-25
Expert Opin Drug Metab Toxicol. 2020-9
Hong Kong Med J. 2020-6
Hum Reprod Update. 2020-4-15
Annu Rev Pathol. 2019-9-3
Arch Gynecol Obstet. 2016-7